Centanafadine
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
JSmol) | |
| |
|
Site | IC50 (nM) | Action | Ref |
---|---|---|---|
SERT | 83 nM | Blocker | [1] |
NET | 6 nM | Blocker | [1] |
DAT | 38 nM | Blocker | [1] |
Centanafadine (
Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance.[5][6] In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine.[7] As of January 2018, Otsuka's pipeline indicates it is in Phase II and III clinical trials for a number of different applications to medical conditions.[8][9][10]
See also
References
- ^ a b c d e "Neurovance's EB-1020 SR for Adult ADHD Shows Stimulant-Like Efficacy and Good Tolerability in Phase 2a Trial" (PDF). Neurovance. Retrieved 14 January 2018.
- ^ "3-Neurotransmitters, 1-Molecule: Optimized Ratios". Neurovance.
- ^ "EB-1020, a Non-Stimulant Norepinephrine and Dopamine - Preferring Reuptake Inhibitor for the Treatment of Adult ADHD" (PDF). Neurovance. Archived from the original (PDF) on 2015-11-17. Retrieved 2015-11-14.
- S2CID 38850652.
- ^ "Euthymics". Ethismos Research Inc. Retrieved 14 January 2018.
- ^ "EUTHYMICS BIOSCIENCE, INC. PRESENTS DATA THAT SUPPORT ADVANCING EB-1020 INTO CLINICAL TRIALS FOR ADULT ADHD" (PDF). Neurovance. December 7, 2011. Retrieved 14 January 2018.
- ^ "Otsuka Pharmaceutical to Acquire Neurovance, Inc". Otsuka. Retrieved 14 January 2018.
- ^ "Otsuka U.S. Research & Development Programs". Otsuka U.S. Otsuka. Retrieved 14 January 2018.[permanent dead link]
- ^ Otsuka Pharmaceutical Development & Commercialization, Inc. (2021-09-17). "A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder".
{{cite journal}}
: Cite journal requires|journal=
(help) - S2CID 266120058. Retrieved 2023-06-26.